Arix Bioscience has announced planned changes to its executive team to prepare for its next phase of growth and development. Dr Joe Anderson, who has served as CEO of Arix since its inception in 2016, will transition to chief investment officer to focus on new investments and work with existing group companies to build and realise value. Joe will continue to chair the Investment Committee and will step down from the Board of Arix. Executive chairman of Arix, Jonathan Peacock, will assume corporate and operating responsibilities and, working closely with the Board of Arix, will lead the process of recruiting a CEO.
